All In Biotech

Drug Trial Radar · NCT00124072

Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

Last checked: Nov 20, 2026Latest source record: Feb 1, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,064 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,064

Actual

Start

Jul 1998

Primary completion

May 2008

Study completion May 2008

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Merck Sharp & Dohme LLC
First posted
Jul 26, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SEARCH is a randomised, double-blind, multi-centre United Kingdom (UK) trial of 12,064 patients with myocardial infarction (MI) prior to study entry which aims to demonstrate whether a more intensive cholesterol lowering regimen using 80 mg simvastatin daily produces a larger and worthwhile reduction in cardiovascular events compared with a standard 20 mg daily regimen and whether reducing blood homocysteine levels with a daily dose of folic acid 2 mg + vitamin B12 1 mg compared with matching placebo produces a worthwhile reduction in vascular disease.

Conditions

  • Cardiovascular Disease

Interventions

  • Simvastatin 20 mg dailyDrug

    Simvastatin 20 mg tablet once daily

  • Folic acid 2 mg + vitamin B12 1 mg dailyDietary supplement

    Folic acid 2 mg + vitamin B12 1 mg tablet once daily

  • Simvastatin 80 mg dailyDrug

    Simvastatin 80 mg tablet once daily

  • PlaceboDrug

    Placebo vitamin B12/folic acid tablet once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Major Vascular Events (MVE)Time frame: 6.7 years median follow-up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CTSU, Richard Doll Building, University of Oxford

    Oxford, Oxon, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.